1.
Reduced ocular perfusion after intravitreal Aflibercept and faricimab: an exploratory study for Tie2 receptor distribution in ophthalmic capillaries.
Schuhmayer Anna C, Karl Nina A M, Pomberger Leon, Eidherr Markus, Khalil Haidar, Kallab Martin et al.
Graefes Arch Clin Exp OphthalmolOct 20250 citationsClinical Trial
This study found Faricimab caused a faster reduction in retinal blood flow than Aflibercept, while both equally reduced choroidal flow. This suggests differing Tie2 receptor distribution, impacting anti-VEGF treatment effects.